call. on to Thank everyone you, the Chip. And good afternoon
we dependent for anemia with thrilled transfusion response of or patients the imetelstat adult MDS ESA. to who agent, to drug XXXX risk or to respond erythropoiesis-stimulating intermediate-X mentioned, lost or in to failed our new have ineligible for submitted in low have treatment Chip have June are As application
permitted imetelstat's designation, the the track requested of NDA. grant that As have under we review priority fast FDA
expect submission. FDA review. in potential That acceptance is XX the communicate the days a of will and NDA date sometime within such of reveal mid-August We PDUFA for
in a review, would Under the approval next second expect in year. expect we quarter potential scenario, we of Under NDA review priority XXXX. of approval timing timing potential quarter standard first the would
quarter authorization potential for the we remain of in XXXX. the US, on a to To outside lower of Union expand imetelstat's submit reach MDS in marketing fourth application European the track risk
for commercialization to As This US, in to initiated the is and we expanded approval. treating which an that program, low to imetelstat apply MDS available or physician await in program potential this EAP, to patients requires in make protocol patients for clinicians FDA Treatment their prior by risk FDA, on patient. us each we a program is enables of based approved access access a June XXXX.
able access low heard academic new need risk and be this and lower MDS have in to treatment patients, program are the express options community both for settings we to We offer pleased physicians their the expanded risk to community. for MDS
expanded transitioned three supply access the future to with approval a potential are of the after within ultimately months program commercial treated FDA imetelstat Patients expected in to be drug.
further investor role and we hosted content during IMerge. on lower These XX were a Geron EHA, at new described, of The the standard imetelstat and care analyses MDS. also in potential its data event. support differentiated from presented risk June these and presentations data existing Chip As from treatments new as of reported ASCO
website We encourage in investors Rami webcast these Drs. leaders on to can Events. key data of you hematologic access which our archived is detail. available hear the and under IMerge investigators, portion Komrokji, investor malignancy There Platzbecker and present the Uwe opinion
purposes the overview an imetelstat ASCO points today, provide and highlighted our call key EHA of our For differentiation the in of of will the I presentation.
treated independence, transfusion is placebo. durable and in rates treated in XX imetelstat MDS. TI, IMerge and with or statistically patients XX-week patients patients week, highly imetelstat PIs for meaningful TI a clinically in improvement week the We with risk compared experienced for lower observed X unprecedented significant by First,
additional week three imetelstat patients approximately nearly months represents exciting, XX% up, Even more a experienced follow responders. TI, with which XX% XX of imetelstat one year treated of of
KOLs anemia differentiation. of of X.X with TI per noted imetelstat rise median deciliter treated malignancy important for EHA ASCO hem hemoglobin and grams eight-week improvement point a Additionally, very of significant that statistically responders a at as
burden have EPO with agents to used with of as the breadth clinically including studied subgroups, MDS observed other most levels. anemia meaningful lower a risk responses been without those patient RS These transfusion and other such with across negative been Second, such not serum results high have of populations treat seen treatments. nor those or patients key MDS well populations, high was to as sideroblast, treat patients, as ring difficult
TI EHA, new responders ring analysis rate burden, durability EPO category prior At and or for sideroblast we TI IPS of risk transfusion important that regardless lower is across presented serum key at-risk similar showing XX-week status, MDS subgroup levels. baseline the subgroups, of
evidence Third, we malignant by mutation of patients, supported reducing on VAF. mechanism lower in by in imetelstat saw measured or responses allele we eliminating In variant imetelstat's cytogenetic or imetelstat's MDS to bone Furthermore, new reduction risk frequency, marrow potential robust of the presented data have alter biology underlying action. burden, reductions treated of clones. and a RSL as
lower indicate risk patients imetelstat data that with may have modifying these totality, disease In potential in MDS.
sustained EHA were improvement also reported encouraging. Fourth, fatigue meaningful treated data versus for outcomes data a in patients patient placebo. at very on imetelstat describe presented These
patients easily blood This that of is specific is lower fatigue importance risk because patient red alleviated MDS cell reported particular experience transfusions. by outcome not
in is fatigue show the in low the patient increase we of improvement treatments lower MDS risk risk in of with associated many for aware Imetelstat current reported first fatigue. an patients. MDS Additionally, an treatment are to are
experience, and grade frequently the prior X consistent Phase reported and with IMerge were adverse In most events. neutropenias clinical thrombocytopenias X X,
treatments with in lower were in severe to as as importantly, may such resolving myelosuppression, or hematologist's bleeding grade or cytopenias rarely prolonged two and such less resulted severe which than consequences, most associated weeks lived, several cases, four clinical Unlike only infection. short cause in other lenalidomide, HMAs most armamentarium, in and imetelstat
imetelstat In lower anemia impactful approved, a for patients. option a we the total, the as very will profile transfusion believe IMerge support in clinical MDS dependent for treatment if data serve of that, risk
have with I'd of combination with available other splenomegaly. been Next, inhibitor and inhibitor they inhibitors, treatment JAK do or relapsed JAK ability patients of patients XX their approximately to a The second improve Phase JAK imetelstat overall on years. dismal once discuss And of five by inhibitors. Approximately survival therapies to dominated action myelofibrosis. refractory discontinue trial of with after face approved XX% is currently mechanisms months. myelofibrosis to symptoms XX in reduce they therapies based in so, our JAK of like X Today, IMpactMF,
the patients, could imetelstat study MF X months, treated patients. transformational for XX overall that in double in Phase historical these imetelstat believe survival JAK was nearly EMBARK We or be compared relapsed inhibitor patients to the controls. In refractory
survival Additionally, of data closely compared of data a cohort EMBARK with improvement therapy. with real lower imetelstat-treated risk overall X Phase available of confirmed patients to death patients treated best in a and for patients comparison world from matched
evidence disease improved Importantly, of with the strong modifying improvements bone to relapsed/refractory in survival in were mutations. marrow primary of clinical of these as in JAK data fibrosis basis the key MF, the reduction driver EMBARK, overall Phase study potential inhibitor These MF X endpoint. survival in the with correlated and there in refractory relapsed and the was imetelstat IMpactMF MS And reductions for patients design other outcomes. and initiation
enrolled when interim planned approximately The have over final have for XX% enrolled XX% died. patients the of patients And planned IMpactMF protocol analysis of the called died. with the planned analysis a
XXXX rates As XX% based rate, on Today, in enrollment for first also guidance to on not the of final be timeline our depends on the enrollment in but rate. over the planning the analysis enrollment the for for be analysis analyses are and to interim study, and an updating of the projected we final XXXX. half in and for and death IMpactMF interim first OS only achieving the death in our trial, half assumptions
the will reflect Because driven and event rates than enrollment planning actual assumptions, and for results different currently uncertain at current times analyses may events is be available these it whether projected. are
resources be led some due can As an for in in recruitment which ongoing and the MF indication and are trials, competing there constraints COVID-XX trials multiple have expected pandemic, enrollment. on challenges site personnel to studying to other for clinical
to MF and enrolled. are trial on is the working the to community closely plan sites and with for the our We trial recruitment trial when clinical continue announce XX%
is this the a survival mentioned, Chip trial primary only with and first As endpoint. as myelofibrosis overall
currently could potential Our MF rates. excited patients treatment investigators study, have dismal a for survival this who that these new very and treatment few remain improve and about the survival of options
was investigator that acute high are is patient this We Phase that risk also to imetelstat in with evaluating IMpress pleased patients MDS. June trial myeloid or relapsed first X in refractory led the dosed leukemia report the
is and human targets that have and of trial in progression This impairing reported cells, describe based leukemic telomerase inhibiting publications AML that on both role mouse disease the and telomerase derived progression. depletes preclinical potentially in leukemic model stem AML which thus
MDS forward potential understanding higher efficacy And to are in and high patient population. about need we risk AML areas. the look refractory of Relapsed more imetelstat this unmet
that, let the provide to With to call Anil? me over commercial turn Anil update. a
